Explore the Agenda
7:15 am Check In & Morning Coffee
8:15 am Chair’s Opening Remarks
Turbocharging mRNA Innovation & Clinical Strategy to Advance the Future of Vaccines & Therapeutics for Patients Faster
8:30 am CEO Think Tank: Unlocking the Next Wave of mRNA-Based Vaccines, Therapeutics & Platforms to Develop Better mRNA Drugs Towards Clinical Reality
9:25 am mRNA 2.0: From Hype to Endurance — Building a Durable Future for a Disruptive Modality
9:45 am Panel Discussion: Harnessing the Potential of mRNA & Circular RNA Technology as a Tool to Advance In Vivo Engineering Cell & CAR-T Therapy
10:30 am Morning Break & Speed Networking
Discovery
Optimizing Novel mRNA-LNP Design & Platform Strategies to Accelerate Discovery Timelines – Chair
Director & Team Leader - mRNA, AstraZeneca
Senior Director, Editas Medicine
11:30 am Circular RNA: From Promise to Reality
Chief Executive Officer, RNAvate
12:00 pm RNA Quality Control: A Sequencing-First Perspective
Head of Scientific Strategy, Eclipse Bio
12:30 pm Recent Progress in mRNA-Based Targeted Protein Degrader Development
Chief Executive Officer & Head of R&D, Genexine
Pre-Clinical Development
Clinical
Manufacturing & CMC
1:00 pm Lunch & Networking Break
Discovery
Discovering Novel mRNA Vaccine & Therapeutic Proof-of-Concepts to Shine Light on Promising New Applications Across Disease Indications – Chair
Director & Team Leader - mRNA, AstraZeneca
Senior Director, Editas Medicine
2:00 pm Selective Agonism of Specific Pattern Recognition Receptors to Generate Next Generation Safe & Effective mRNA Vaccines & Therapeutics
President, Chairman & CEO, Celestial Therapeutics
2:30 pm Novel Efficient Cap Analog & Rapid Eliminated Ionizable Lipid Improve the Efficacy & Safety of mRNA-Based Protein Replacement Therapy
Co-Founder & Chief Operating Officer, Henovcom
- mRNAs with LZCap® exhibit superior pharmacokinetics profile in vivo studies across multiple species, including rats, beagle dogs, pigs, and cynomolgus monkeys
- Novel ionizable lipid-based LNPs achieve high transfection efficiency with rapid in vivo clearance and favorable safety profiles
- Preclinical studies of protein replacement pipelines demonstrate robust efficacy and excellent tolerability
3:00 pm mRNA Lipid Nanoparticles for the Treatment of Obesity
Chief Executive Officer, Grann Pharmaceuticals
Pre-Clinical Development
Clinical
Manufacturing & CMC
3:30 pm Afternoon Break & Poster Session
Discovery
Accelerating Novel Target Discovery for Targeted mRNA Therapeutics to Widen mRNA Application – Chair
Director & Team Leader - mRNA, AstraZeneca
Senior Director, Editas Medicine
4:00 pm Exosome Inhibitors of Cardiac Apoptosis Induced by STEMIN & YAP5SA ModeRNA, the Next Breakthrough in Treating Heart Failure
Chief Scientific Officer, Animatus Biosciences
4:30 pm Engineering mRNA for Success: Bayesian Networks for Maximum Expression & Tissue Specificity
GM, Officinae Bio, part of Maravai LifeSciences
5:00 pm Targeted mRNA Therapeutics
Assistant Professor - Pharmacology, University of Pennsylvania
Pre-Clinical Development
Clinical
Manufacturing & CMC